Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake - Wikidata - wikimedia - TriplyDB

Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake

Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake

http://www.wikidata.org/entity/Q36533826

about

Targeted Radionuclide Therapy: Practical Applications and Future Prospects (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report A Review of Imaging Methods for Prostate Cancer Detection.Positron emission tomography (PET) in primary prostate cancer staging and risk assessment Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis Synthesis, Radiolabeling, and Biological Evaluation of (R)- and (S)-2-Amino-5-[(18)F]fluoro-2-methylpentanoic Acid ((R)-, (S)-[(18)F]FAMPe) as Potential Positron Emission Tomography Tracers for Brain Tumors.Reproducibility and reliability of anti-3-[¹⁸F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis Translational Molecular Imaging of Prostate Cancer.PET Tracers Beyond FDG in Prostate Cancer.PET Molecular Imaging-Directed Biopsy: A Review.Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients.Phase IIa Clinical Trial of Trans-1-Amino-3-(18)F-Fluoro-Cyclobutane Carboxylic Acid in Metastatic Prostate Cancer.Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer PET-directed, 3D Ultrasound-guided prostate biopsy.¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.Molecular imaging and fusion targeted biopsy of the prostate.

P2860

Q26745926-95027DEB-EA15-4D8F-9636-64EA9CF1B321 Q26747480-C021CE52-79B9-4175-96C3-86E9E10A95E1 Q26766398-14385D4D-0E7B-4FA5-B93B-FCC9BA840F21 Q33890153-898CC2A0-7654-4B4B-8AFD-E4FCC63EA6FF Q34139498-553F7B62-398E-4AE9-A560-EBA0FCBAAC56 Q34451031-584DADA8-F0FC-4C18-A120-54D7FF6D3D72 Q34522627-E7B29DCA-8969-42E9-B945-4EC7DF20B6BE Q34681143-628F759E-D1E2-42E2-BBA0-B17BCD214677 Q35764792-FF6A7586-1EA5-4F8A-AA41-744BEA545EA8 Q36839766-292C97DA-5FBF-4B66-8393-0BAB92F089AD Q37244969-A6B5ED15-416E-4EAB-8FD3-8D09C014B7FD Q39003086-772C4F29-1D28-489A-8151-B90AE9211424 Q39306671-987742F4-9961-4D7F-A324-61176621EAC9 Q39438297-F92A82FB-D8C2-4232-BBCD-2DA76C1EC503 Q40741628-A0397A98-102E-4ACA-A82A-E6F2C8F24A01 Q41862609-C84D068E-4B09-48B9-A5F6-EACDED987172 Q42379563-3F25042B-EFB9-4BE0-9BE6-C722BE2A7D8A Q42991361-5C70C53D-1FCF-42E5-99FD-41858C0C5FDC Q43156292-8FEC2A5D-89C0-40E6-946A-10791ECC8F62 Q47608215-D1514B28-9F60-4948-85F4-D570A1382F31

P2860

Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake

http://www.wikidata.org/entity/Q36533826

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Characterization of primary pr ...... (anti-3-[(18)F] FACBC) uptake

@ast

Characterization of primary pr ...... (anti-3-[(18)F] FACBC) uptake

@en

type

label

Characterization of primary pr ...... (anti-3-[(18)F] FACBC) uptake

@ast

Characterization of primary pr ...... (anti-3-[(18)F] FACBC) uptake

@en

prefLabel

Characterization of primary pr ...... (anti-3-[(18)F] FACBC) uptake

@ast

Characterization of primary pr ...... (anti-3-[(18)F] FACBC) uptake

@en

P1433

Q36533826-F607D049-0EA8-4F6E-BFB6-7C25E483CD10

P1476

Q36533826-AB28F98E-D4EE-46D3-94DD-D3E999944B5C

P2093

Q36533826-00CDC155-8FF3-49C9-9B7F-850BFDB4ED1C

Q36533826-13FD5826-095B-4EC9-8F21-8B22E9F9B9B3

Q36533826-1DFBB60A-0E40-4A16-8049-C8C2AA937983

Q36533826-39C3AA4C-A448-4DD3-A493-26E62FE985A6

Q36533826-5D2249D8-75A9-46C1-B5A8-3B6021C58D29

Q36533826-5DB131FF-5E42-47A2-A9FA-C2EAB4EF7457

Q36533826-65C9EF38-BCB5-4C18-9652-A33F34DD36BC

Q36533826-754E08C6-CAD3-4BFB-BD6E-762D320F5FC0

Q36533826-7B1F6DA6-E949-4385-ABEB-D50E326161D7

Q36533826-93929F1A-4766-4801-B443-A8A811047E0D

P2860

Q36533826-00EE0FD0-1C31-403B-ADB5-19D4B944D35D

Q36533826-01523DE5-64F4-49A4-B8E9-B9CC0BB403CD

Q36533826-05EFC3D3-4B0A-40E0-9E67-13B11679310D

Q36533826-07499DFD-07CC-4D50-80FB-AE2A77027A34

Q36533826-14C78BD0-B98F-4E96-AE74-08682B0EE5D3

Q36533826-192062A7-A8B6-41B1-A0B1-01B5E324A7FA

Q36533826-1FC2D24A-2344-4BAE-B2FE-A4D1E6A3CC8D

Q36533826-24C3A7F5-064F-4822-B094-CEFB84CD271B

Q36533826-2EA53DA7-6DE5-4E82-8C15-2F6D8BFA0318

Q36533826-2F48107E-A693-4B03-B739-B730B068E536

P304

Q36533826-8A5D8811-55DA-4184-96C0-44982573458C

P31

Q36533826-21DD399C-B3B6-4B23-A32F-696DC67D6475

P433

Q36533826-AF01DF06-9471-4AD8-91D9-7CE247BCE751

P478

Q36533826-C3CA2450-EA77-4D26-938E-2C58BAB37C45

P577

Q36533826-0174A6D8-A97E-4920-B555-C3F6C66EC046

P698

Q36533826-39522509-CBEB-4FFC-BEFB-685149FDA967

P932

Q36533826-FE9F8079-E647-4D04-A4A3-ECD9C06AE0A1

P1433

American journal of nuclear medicine and molecular imaging

P1476

Characterization of primary pr ...... (anti-3-[(18)F] FACBC) uptake

@en

P2093

Adeboye O Osunkoya

http://www.w3.org/2001/XMLSchema#string

Baowei Fei

http://www.w3.org/2001/XMLSchema#string

Bital Savir-Baruch

http://www.w3.org/2001/XMLSchema#string

Carlos S Moreno

http://www.w3.org/2001/XMLSchema#string

David M Schuster

http://www.w3.org/2001/XMLSchema#string

Jonathon A Nye

http://www.w3.org/2001/XMLSchema#string

Mark M Goodman

http://www.w3.org/2001/XMLSchema#string

Peter T Nieh

http://www.w3.org/2001/XMLSchema#string

Pooneh A Taleghani

http://www.w3.org/2001/XMLSchema#string

Raghuveer K Halkar

http://www.w3.org/2001/XMLSchema#string

P2860

Positron emission tomography imaging of prostate cancer

Cancer statistics, 2012

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

Positron emission tomography for prostate, bladder, and renal cancer.

Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?

11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation.

Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.

Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents.

P304

85-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23342303

http://www.w3.org/2001/XMLSchema#string

P932

3545368

http://www.w3.org/2001/XMLSchema#string